News

UroToday3d
Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications.
The role of extended pelvic lymph-node dissection (ePLND) in prostate cancer has been revisited in light of evidence from studies on staging via prostate-specific membrane antigen positron emission ...
UroToday3d
Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.
While radiation therapy (RT) is one of the primary treatment modalities used in the treatment of cancer, patients often experience toxicity during or after treatment. RT-induced genitourinary (GU) ...
UroToday4d
Diagnostic Accuracy of Combination of Multiparametric MRI PI-RADS Score v2.1 and Prostate-Specific Antigen Density for Prostate Cancer Detection.
Introduction Prostate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. The Prostate Imaging-Reporting and Data System version 2.1 (PI-RADS v2.1) scoring system using ...
UroToday4d
Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients.
Radium- 223 and Lutetium- 177 prostate-specific membrane antigen radioligand therapy (Lu- 177-PSMA) are approved for the treatment of patients with metastatic castration-resistant prostate cancer ...
UroToday6d
Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis.
To evaluate the role of PSMA PET/CT-guided salvage radiotherapy (sRT) in improving long-term biochemical recurrence-free survival (bRFS) in patients with biochemical recurrence (BCR) or PSA ...
UroToday4d
The association between statin use, genetic variation, and prostate cancer risk.
The association between statin medication use and prostate cancer remains inconclusive. Evidence shows that genetic variation modifies lipid-lowering efficacy of statins, however, there are limited ...
UroToday4d
Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes - Beyond the Abstract
Platinum-based neoadjuvant chemotherapy (NAC) is a well-established treatment strategy for muscle-invasive bladder cancer (MIBC) prior to radical cystectomy (RC), offering a proven survival benefit.
UroToday4d
Assessment of Compliance With ASCO Language of Respect Guidelines in Renal Cell Carcinoma Abstracts.
The ASCO Language of Respect (LOR) Guidelines were developed in 2020 to promote patient-respectful language in abstracts and presentations. We assessed adherence to LOR guidelines among renal cell ...
UroToday4d
Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies.
Non-muscle-invasive bladder cancer (NMIBC) is a common malignancy worldwide. While Bacillus Calmette-Guérin (BCG) is standard of care for treatment for most patients with high-risk NMIBC, many will ...
UroToday6d
Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors.
Cytoreductive nephrectomy following immune checkpoint blockade (ICB) in metastatic renal cell carcinoma remains controversial, with limited data on its clinical and pathological outcomes. This study ...
UroToday4d
Cancer-Related Masculine Threat in Young Adult Testicular Cancer Survivors: Associations With Biobehavioral Symptoms.
Cancer and cancer treatment have been experienced by some men as a threat to masculinity. Cancer-related masculine threat (CMT) reflects perceptions that cancer and cancer-related change are ...